Cellectis S.A. ADR
Cellectis S.A. ADR is a clinical-stage biotechnology company focused on gene editing and cell therapy. Cellectis develops gene-edited, off-the-shelf immunotherapies designed to target cancer, with a portfolio centered on allogeneic CAR T-cell product candidates and other engineered cell and gene therapy programs. Its current work spans hematologic cancers and select solid tumor indications, using proprietary genome-editing technology to create therapies that can be manufactured in a standardized form. The company also advances gene-edited hematopoietic stem and progenitor cell research for additional therapeutic applications. Based in Paris, France, Cellectis serves the biopharmaceutical sector by contributing specialized platforms and product candidates that support the broader development of next-generation cancer and gene therapy treatments.
$1.04
-$0.06 (-5.88%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-45.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 75.8% YoY with margins expanding 98.1pp. However, free cash flow softened 324%, worth monitoring whether this is timing or structural.
Free cash flow declined 324% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$43M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$57M
▲ +75.8% YoY
Net Income (TTM)
-$65M
▼ -83.9% YoY
Op. Margin
-102.52%
▲ +98.1pp YoY
ROIC
-13.43%
▲ +10.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$45M
▼ -324.2% YoY
Op. Cash Flow (TTM)
-$42M
▼ -281.3% YoY
Net Debt
-$118M
Net Cash Position
Cash & Equiv.
$209M
3Y CAGR: +56.1%
Continue Research
Is Cellectis S.A. ADR (CLLS) overvalued?
Cellectis S.A. ADR (CLLS)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cellectis S.A. ADR scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Cellectis S.A. ADR a high-quality business?+
Cellectis S.A. ADR scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -102.5% operating margin and a -13.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Cellectis S.A. ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh CLLS's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.